ABOUT US

 

sRNAlytics has developed a game changing technology capable of classifying patient samples with binary accuracy. To do this we utilize a proprietary software suite developed by our founder, Dr. David W. Salzman that identifies small RNA biomarkers. The products we create address an immediate need to incorporate biomarkers into drug development to satisfy FDA requirements, de-risk programs, and unlock billions of dollars through cost-savings and accelerated revenue realization.

Two provisional patent applications developed by our legal team at Morgan Lewis protect our method, and Huntington’s Disease-specific biomarkers that classify disease stage, prognosis, and progression. These biomarkers, and by extension our software suite, have been validated through our academic collaborator, Dr. Richard H. Myers at Boston University.

OUR SOFTWARE PLATFORM TECHNOLOGY

 

 

Our flexible software suite identifies small RNA biomarkers:
- to meet any business or clinical need
- for any disease or indication
- in any species
- from any sample source

Our software suite is a plug-and-play system that can identify custom biomarker panels to meet the specific needs of any client.

APPROACH

OUR TEAM

 

sRNAlyticsHeadShots_Dave2.png

David W Salzman, Ph.D.
Founder and CEO

As founder and CEO of sRNAlyics, David leads all of the science and technological development required for identifying small RNA diagnostics, targeted assay design, validation and subsequent product development. This includes: establishing a software suite to execute data processing and analysis, sample sourcing, and target selection. David also drives business development by facilitating patent protection on IP, forming strategic partnerships with key opinion leaders, universities, and outside institutions.

David brings over 14 years of research expertise and insight in microRNA and small RNA biology with an emphasis on biogenesis, activity, and detection. He also has experience in developing clinical/pre-clinincal biomarker, PK/PD, diagnostic assay development in his a previous role as a Scientist at Biogen, and postdoctoral fellow at the Yale School of Medicine. David earned his Ph.D. from the University of Connecticut in Molecular Biology and Biochemistry, and a B.S. from the University of Hartford in Environmental Science.

David served as the CSO of Mira Dx where he lead projects to identify, develop, and commercialize germline DNA biomarkers for radiation and immuno-oncology therapeutic treatment response, outcome, and toxicty across multiple cancer types.

View his publication record here

 

sRNAlyticsHeadShots_Nathan.png

Nathan Ray
CTO

Nathan brings 20 years of experience in software engineering, with a strong focus toward efficient and reliable signal extraction from large, noisy datasets, including computer vision, web analytics, tracking objects through multi-source data fusion, and natural language search. As Vice President of Technology at Textaurant, Nathan was the lead developer and manager of a small team of engineers producing a web-based seating management toolkit; in <5 years from development-to-sales the company was acquired. Most recently, Nathan was brought on to TripAdvisor to improve the reliability and efficiency of their search tools, reducing run times by a factor of ten thousand, and memory requirements  by a factor of ten, while improving search accuracy.

 

sRNAlyticsHeadShots_Alan.png

Alan P Salzman, Ph.D.
COO

As the Director of Technology, Alan leads projects for product testing, development, feasibility and commercialization in the high-tech space. Additionally, he supports strategic business initiatives, as he played a key role in the acquisition and restructuring of RadioShack, which lead to the subsequent formation of General Wireless Operations dba RadioShack. Alan has over 45 years of expertise in high-tech engineering, and has a proven and decorated history of expertise in process development and product management.

Prior to joining Gee Partnership, Alan served as the Senior Product Development Architect at Dell. Before that he was the Director of 3GSM Global Portfolio Management, the Director of Product Operations for Europe, Middle East, and Africa, the Director of Engineering for CDMA Performance Category mobile phone development and Director of CDMA System and Field Testing. Prior to that he was the Lead Engineering Manager at Bell Laboratories for over 20 years where he worked on breakthrough innovations and technologies such as high speed cable, satellite transmission systems, wireless infrastructure, fiber-to-the-home, loop plant electronics and wired products.

Alan earned a Ph.D. in Applied Mechanics and Mathematics, an M.S. in Applied Mechanics and a B.S. in Aerospace Engineering from the NYU Polytechnic School of Engineering.

 

sRNAlyticsHeadShots_Carrie.png

Carrie Carson
VP of Business Development

As both a scientist and an MBA, Carrie brings a unique lens to strategize and solve complicated challenges. She has previous experience detailing competitive market landscapes, and conducting due diligence in the biotech sector. Carrie earned a BS in Biochemistry from Temple University, with a focus in medical chemistry. After completing her degree, she joined the research group in the Department of Microbiology C3J Therapeutics. Carrie is pursuing her MBA at Kenan-Flager UNC Business School.  

 

SCIENTIFIC ADVISORY BOARD

sRNAlyticsHeadShots_Richard.png

Richard H. Myers, Ph.D.
Director of the Neurogenetics Laboratory
Director of the Genome Science Institute at the Boston University School of Medicine
Professor in the Department of Neurology at the Boston University School of Medicine
Professor in the Bioinformatics at the Boston University School of Arts and Sciences
Professor in the Genetics Program at the Boston University School of Medicine
Professor in the Biostatistics Program at the Boston University School of Public Health

Aubrey Milunsky Chair in Human Genetics at the Boston University School of Medicine

Richard is a distinguished scientist and Professor at the Boston University School of Medicine and School of Public Health. Richard brings over 30 years of research excellence in the neurological disease space. In 1993, Richard co-discovered the gene that causes Huntington’s disease, and has published over 100 manuscripts establishing himself as a subject matter expert. He has been a member of the New England Huntington’s disease “Center Without Walls” since its inception in 1980. His extensive research efforts have helped drive innovation and insight into the etiology and mechanisms for onset, and characterizing gene expression and genetic modifiers of Parkinson’s and Alzheimer’s Disease.

View his publication record here
 

sRNAlyticsHeadShots_Joanne.png

Joanne B Weidhaas, MD, Ph.D., MSM
Professor of Radiation Oncology at the David Geffen School of Medicine UCLA
Co-Founder of MiraDx
Founder of MiraKind

Joanne is a co-founder of MiraDx and Professor at the David Geffen School of Medicine at UCLA, in the Department of Therapeutic Radiology. Her pioneering research led to the co-discovery of the KRAS-variant, a strong predictor of cancer risk and tumor biology. Her passion for empowering individuals to take charge of their health led her to found MiraDx, a genomics company dedicated to giving people and their doctors actionable information to prevent and treat cancer more effectively.

Joanne completed her oncology training at Memorial Sloan-Kettering Cancer Center and previously served as the Chief of the Breast Cancer Radiation Service at Yale Cancer Center and the Section Chief, Breast Cancer, Yale Cancer Center. She has recently moved to UCLA  as Division Head, Translational Research. Her dual role as a clinician and a researcher enables her to apply genetic breakthroughs to the benefit of her patients.

Joanne earned an MD/Ph.D. from Tufts University, and completed her Residency in Oncology at the Memorial Sloan-Kettering Cancer Center. She earned a Masters in Business Management from Stanford Business School. She holds a BS in biology from Yale University.

View her publication record here

sRNAlyticsHeadShots_Melanie.png

Melanie Leitner Ph.D.
Founder of Accelerating NeuroVentures

Melanie is an internationally recognized thought leader in Amyotrophic Lateral Sclerosis (ALS), and an expert in the incentivized prize space. Melanie advises companies, foundations, and investors interested in translating neuroscience discoveries into breakthroughs for patients. She has spent her career in government, academia, and both the non-profit and for-profit sectors, breaking down barriers and promoting cross-disciplinary collaboration.

Before founding Accelerating NeuroVentures, Melanie was an Associate Director at Biogen, where she served as a key member of the ALS clinical development and program teams. She was a cross functional-player on both the scientific and business development teams where she was responsible for vetting scientific strategy, collaborations, and acquisitions. Prior to that, she was the CSO of Prize4Life, where she developed and managed the programmatic initiatives of the organization designed to fill translational gaps in ALS research and drug development.

Melanie earned a Ph.D. in Neuroscience from Washington University in St.Louis. She holds a SBc in Neural Sciences from Brown University.

View her Publication Record here

 

LEGAL ADVISORS

sRNAlyticsHeadShots_Mark.png

Mark Hayman, PhD
Partner at Morgan, Lewis & Bockius LLP

Dr. Hayman is a co-leader of the life sciences patent practice in Morgan Lewis’ Boston Office. Mark brings 15 years of experience in patent counseling and portfolio development, and specializes in building patent estates for emerging life sciences companies. Mark earned his Ph.D. in microbiology from the University at Buffalo in 2000 and his J.D. from the University of Pittsburgh School of Law in 2003.

 

sRNAlyticsHeadShots_Peter.png

Peter B. Finn
Partner and Chair, Rubin and Rudman LLP

Peter has over 35 years of experience representing representing biotechnology and high technology companies in all aspects of corporate law including negotiating and drafting fee for service and licensing contracts, technology transfer, strategic alliances, venture capital and M&A. He has assisted in the launch of more than fifty biotechnology companies, and has lead venture capital financing for companies in all stages of development, in excess of $500M. Peter represents a wide range of clients and has established himself as a leading biotech lawyer in the Boston and Cambridge biotech cluster.

NEWS

sRNAlytics to Accelerate its Biomarker Discovery Platform and Services at IndieBio

December 08, 2017
By BioSpace.com Breaking News Staff

 

Massachusetts Startup sRNAlytics Develops Potent Small RNA Biomarker Sequencing Data

August 25, 2017
By Alex Keown, BioSpace.com Breaking News Staff

 

PARTNER WITH US

Have you identified a clinical or business need where a biomarker is needed?

If so, contact us at info@srnalytics.com or fill out the online form and we'll contact you to discuss your needs and challenges.

Name *
Name